32.2003.19% ( -1.060 )
Delay Closed: Nov 17, 16:08:15Valuation
Current ValuationThe current P/E ratio is -20.84, above the reasonable range, cheaper than 0% of the time in the past 1 years, and the industry ranks 63/78, the industry Median -4.90.
-20.84xP/E
HK$32.20Stock price
HK$-1.55Earnings per share
-20.84xP/E
Stock priceHK$32.20Earnings per shareHK$-1.55
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -41.14x
- Typical range
- -55.87x–-32.62x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0150300450600
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
09926HKAKESO | -52.32x | 69.66% | HK$58.26B |
09688HKZAI LAB | -15.17x | 17.69% | HK$23.62B |
01877HKJUNSHI BIO | -31.53x | 83.59% | HK$14.49B |
02627HKAB&B BIO-TECH-B | -46.87x | -- | HK$11.54B |
06855HKASCENTAGE | -5.68x | 19.15% | HK$9.61B |
01952HKEVEREST MED | -142.81x | 326.79% | HK$8.87B |
02616HKCSTONE PHARMA-B | -18.07x | 1.09% | HK$8.72B |
07666HKMETIS TECHBIO-P | -21.17x | 96.67% | HK$8.62B |
09606HKDUALITYBIO-B | -5.13x | 85.35% | HK$8.49B |
02493HKMABWELL-B | -6.50x | -- | HK$7.95B |
02595HKGENFLEET-B | -4.90x | 66.07% | HK$7.42B |
02335HKMICOT PHARMA-B | -16.33x | 37.52% | HK$6.85B |
06938HKRIBOLIFE-B | -33.43x | 29.56% | HK$6.53B |
09887HKLEADS BIOLABS-B | -20.84x | 3.57% | HK$6.40B |
02171HKCARSGEN-B | -60.48x | 52.33% | HK$6.21B |
09966HKALPHAMAB-B | -26.07x | -- | HK$5.28B |
00775HKCKLIFE SCIENCES | -75.76x | -- | HK$4.90B |
01672HKASCLETIS-B | -6.74x | 78.53% | HK$4.59B |
02256HKABBISKO-B | -8.40x | 814.43% | HK$4.51B |
01779HKLONGBIO-B | -15.42x | -- | HK$3.84B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
